美完成接种者“突破”感染病例上升 但疫苗扔有助预防重症


FOTILE Range Hoods


美完成接种者“突破”感染病例上升 但疫苗扔有助预防重症

文 / 陈慧璋

8/24/2021

美国CDC数据显示,3.2%已完成冠病疫苗接种的冠病患者需要住院,但只有0.05%进入加护病房,只有0.25%需要使用呼吸机。没有接种冠病疫苗的患者方面,7.5%需要住院,1.5%进入加护病房,0.5%需要使用呼吸机。(法新社)

(早报讯)美国疾病控制与预防中心(CDC)周二(24日)发布的每周死亡与疾病报告显示,发生在完成冠病疫苗接种者身上的“突破”感染病例有所上升。不过,冠病疫苗确实有助保护人们避免出现重症情况。

路透社报道,美国官员表示,洛杉矶县居民中约25%感染了严重急性呼吸综合征冠状病毒2(SARS-CoV-2,即冠病原始毒株)的人,在5月至7月25日期间已完成冠病疫苗接种。当时是更具传染性的变种冠病病毒包括德尔塔变种病毒的肆虐时期。

CDC正根据洛杉矶县研究等不同群组的数据来判断美国人是否需要接种第三剂冠病疫苗以增强免疫力。美国政府科学家已在上周制定了一项从9月20日开始施打加强剂的策略,仍在等待美国食品与药物管理局(FDA)的审批。



周二发布的新数据涉及洛杉矶县16岁及以上居民中出现的超过4万3000起确诊病例。其中1万零895起(25.3%)已完成冠病疫苗接种,1413起(3.3%)局部接种了冠病疫苗,而3万零801起(71.4%)是没有接种冠病疫苗的人。

数据也显示,3.2%已完成冠病疫苗接种的冠病患者需要住院,但其中只有0.05%进入加护病房,只有0.25%需要使用呼吸机。

没有接种冠病疫苗的患者方面,7.5%需要住院,1.5%进入加护病房,0.5%需要使用呼吸机。

除了洛杉矶县的数据,美国CDC周二还发布了对医护人员进行的HEROES研究的更新报告。该研究显示,在八个暴发疫情的州属,前线医护人员的冠病疫苗有效性显著下降。

在德尔塔变种病毒肆虐期间开展的研究结果显示,冠病疫苗的有效性降低至66%,比德尔塔变种病毒出现前91%的有效性低了许多。

原文链接>>



Nearly 100 Positive COVID-19 Tests Linked to Illinois Summer Camp

6/29/2021

QUINCY, Ill. (WGEM/CNN) – Nearly 100 teenagers and staff tested positive for COVID-19 after attending a church camp in rural Illinois.

‘The Crossing Camp’ was held in mid-June in Rushville. While majority of the campers and staff were eligible for the vaccine, Illinois Department of Health officials said few had been inoculated. 

The health department said the camp did not require masks indoor. At least one young adult was hospitalized as a result of the outbreak.

Source>>



The Delta variant appears to have tripled to 31% of all US coronavirus cases in just 11 days. It’s more dangerous than other variants and could imperil the country’s recovery.

By Marianne Guenot

6/21/2021

covid vaccine
A medical assistant administering a COVID-19 vaccine dose in Los Angeles. Mario Tama/Getty Image

As of Wednesday, the Delta coronavirus variant may have been responsible for 31% of all coronavirus cases in the US, according to an estimate by the Financial Times.

Previous data from the Centers for Disease Control and Prevention put that share of cases at about 10% as of June 5 and 2.7% on May 22.

The Financial Times estimate, based on available sequencing data, would mean the share of Delta-variant infections in the US tripled in just 11 days.

The CDC has not yet released data on the rate of Delta-variant cases after June 5 in the US.



Dr. Rochelle Walensky, the director of the CDC, warned last week that the Delta variant could soon become dominant in the US.

And on Sunday, the former Food and Drug Administration chief Scott Gottlieb warned that the Delta variant could lead to a surge of cases in the fall even if 75% of eligible Americans were vaccinated by then.

The variant, which was first identified in India and is also called B.1.617.2, appears to be 60% more transmissible than the variant that is now still dominant in the US, the Alpha variant.

Data from the UK, where the Delta variant is thought to make up about 90% of current coronavirus cases, also suggests that the risk of hospitalization is higher for unvaccinated people with this variant.



The Delta variant also appears to more likely to evade the protection given by partial vaccinations.

Research suggests a single shot of the Pfizer-BioNTech or Oxford University-AstraZeneca coronavirus vaccines may give just 33% protection against symptomatic COVID-19 cases with the Delta variant, compared with at least 88% for other variants.

Two doses of the Pfizer-BioNTech or Oxford-AstraZeneca shot have been found to be protective against hospitalization from the variant, however.

It is not clear what protection other vaccines give against this variant.

On Friday, President Joe Biden warned that the Delta variant was “particularly dangerous for young people,” who are less likely to be vaccinated than older adults and are more socially active.

He also urged all Americans to get second doses of vaccines that require them.

As of Monday, 45% of Americans were fully vaccinated and 53% had received one dose, according to data from the CDC. The pace of vaccination, however, has fallen in the past two months.

Source: https://www.businessinsider.com/delta-coronavirus-variant-growing-in-us-could-imperil-recovery-2021-6



Six Spaces Home Staging

This image has an empty alt attribute; its file name is Six-Spaces-Home-Staging.jpg
Fairfax, VA
Contact: Hongliang Zhang
Tel: 571-474-8885
Email: zhl19740122@gmail.com

打完疫苗后却确诊 专家:疫苗并不会马上出现保护作用

文 / 潘万莉

12/30/2020

传染病专家表示,疫苗并不会马上出现保护作用,至少得等10至14天后才有效。(路透社)

(早报讯)美国一名急诊科护士18日接种冠病疫苗后,仍旧在八天后确诊。传染病专家表示,疫苗并不会马上出现保护作用,至少得等10至14天后才有效;另外,冠状病毒的潜伏期较长,护士也可能在注射前就染疫。

根据报道,美国加州圣地牙哥一名45岁急诊室护士马修在18日接种了辉瑞的冠病疫苗,当时出现的副作用仅有手臂肌肉酸痛,没想到他却在24日出现发冷、全身肌肉疼痛和疲劳等症状,最后在26日经检测后发现确诊冠病。



圣地牙哥家庭健康中心传染病专家拉莫斯表示,这种状况其实并不意外,因为疫苗接种后,大约还需要10至14天才会出现防护效果,且还需要注射第二剂疫苗,“第一次注射的保护力约在50%,第二次则会提高到95%。”

拉莫斯说,这一切都代表着,尽管疫苗是一切结束的开始,但还是必须坚持基本的公卫守则,“总而言之,戴口罩、洗手并保持社交距离才是最重要的防疫措施。”

原文链接>>



福奇:冠病早期治疗或是走向疫苗的桥梁

文 / 林煇智

9/27/2020

美国国家过敏和传染病研究所所长安福奇称,美国当局正在研究基于抗体的药物,以及其他来自康复患者的血液制品和抗病毒药作为早期治疗方法,而其目的是为了防止患者出现严重肺损伤。(彭博社)

(早报讯)美国国家过敏和传染病研究所所长安福奇称,阻止2019冠状病毒疾病(COVID-19)在体内传播的单克隆抗体(monoclonal antibody),是疫苗面市前避免病毒导致严重疾病的策略之一。

彭博社报道,福奇表示,当局在研究把基于抗体的药物,以及其他来自康复患者的血液制品和抗病毒药作为早期治疗方法,而其目的是为了防止患者出现严重肺损伤。

福奇说:“我们现在非常重视早期感染的治疗或预防感染。那是通往疫苗的桥梁。”

福奇说,在美国针对SARS-CoV-2的免疫可能会于11月或12月开始,不过可能至少要到2021年第三季度才能让大多数美国人得到保护,以大大减轻这种大流行病毒的威胁。

Jessie Huang, Mortgage Loan Professional, Meridian Bank
Jessie Huang, Mortgage Loan Professional, Meridian Bank Mortgage

福奇说,美国在12月份可能生产1亿剂疫苗,而美国旗下的六家药厂公司打算在明年4月前生产7亿剂。

原文链接>>